Showing results (121-130 of 245) with videos related to

Sort By:
Pageof 25
Liver Cancer|October 1, 2020
Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1Naoshi Nishida, Kazuko Sakai, Masahiro Morita, et al.
Digestive Diseases (Basel, Switzerland)|November 8, 2014
Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinomaTadaaki Arizumi, Kazuomi Ueshima, Hirokazu Chishina, et al.
Therapeutic Advances in Gastroenterology|July 2, 2016
Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancerKosuke Minaga, Masayuki Kitano, Hiroki Sakamoto, et al.
Digestive Diseases (Basel, Switzerland)|December 22, 2012
Risk of hepatocellular carcinoma development in cases of hepatitis C treated by long-term, low-dose PEG-IFNα-2aSatoru Hagiwara, Toshiharu Sakurai, Masahiro Takita, et al.
Journal of Gastroenterology|February 7, 2014
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinomaTadaaki Arizumi, Kazuomi Ueshima, Haruhiko Takeda, et al.
World Journal of Gastroenterology|April 6, 2019
Risk factors for local recurrence and appropriate surveillance interval after endoscopic resectionYoriaki Komeda, Tomohiro Watanabe, Toshiharu Sakurai, et al.
Digestive Diseases (Basel, Switzerland)|November 8, 2014
Radiofrequency ablation for hepatocellular carcinoma measuring 2 cm or smaller: results and risk factors for local recurrenceMasashi Kono, Tatsuo Inoue, Masatoshi Kudo, et al.
Digestive Diseases (Basel, Switzerland)|November 8, 2014
Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenibTadaaki Arizumi, Kazuomi Ueshima, Hirokazu Chishina, et al.
Liver Cancer|December 24, 2021
Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular CarcinomaTomoko Aoki, Naoshi Nishida, Kazuomi Ueshima, et al.
BMC Gastroenterology|June 23, 2026
Curative treatment is feasible for recurrent hepatocellular carcinoma regardless of recurrence pattern after hepatitis C virus eradication with interferon-free direct-acting antiviral therapySatoru Hagiwara, Takuya Matsubara, Naoya Omaru, et al.
Pageof 25